Welcome!
• Home • FAQs
• Site Map
Weather
• Contacts
Free Service Appreciation
Choose Pondside Web Productions for your hosting and web design needs!

Introducing PREVENILE™ - an Innovative West Nile Virus Vaccine

from Intervet Canada Ltd.

March 5, 2008

Whitby, ON --- Intervet Canada Ltd. is proud to introduce PREVENILE™ - an extraordinary West Nile virus vaccine. “PREVENILE is truly an extremely important new vaccine,” said Dr. Rick Conrad, Equine Technical Services consultant for Intervet Canada Ltd. “This vaccine has achieved what every practitioner would like to have in a vaccine – single vaccination, non-adjuvanted and very safe, cell mediated long lasting immunity and fast acting protection achieved in 10 days.”

PREVENILE is the first West Nile vaccine with approved claims to prevent viremia and as an aid in the prevention of disease and encephalitis caused by West Nile virus infection. PREVENILE is the only one dose West Nile virus vaccine with a full 12 months of safe, convenient, proven West Nile protection. The safety and convenience of PREVENILE serves important yet unmet practitioner needs. This non-adjuvanted vaccine requires only one dose and has been shown to be >99% reaction free in safety studies. In a small study using yearling horses, it was demonstrated that onset of immunity may be achieved as early as 10 days following a single vaccination of a field dose.

PREVENILE has been available in the US for over a year with widespread success.

PREVENILE utilizes a live attenuated human Yellow Fever chimera virus with certain structural genes exchanged for those of West Nile virus by ChimeriVax™ technology. Immunogenicity and onset of immunity studies utilized a severe intrathecal (injection into the cerebrospinal fluid) challenge model post-vaccination to demonstrate efficacy.

For additional product, technical or order information please contact your Intervet Technical Sales Representative, log on to www.intervet.ca or call 1-800-268-4257.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its website is www.schering-plough.com. The Animal Health business is focused on the research, development, manufacturing and marketing of animal health products. Building on a wide base of innovative, high quality veterinary products, the combined business represents one of the world's leading companies in the field of animal health and is the world market leader in the production of animal health vaccines. The business has offices in more than 50 countries and markets its products in over 120 countries. On a combined basis, our company operates 28 Animal Health manufacturing sites and 22 Research & Development sites around the world.

Prevenile is a trademark of Intervet Inc. or an affiliate. ChimeriVax is a trademark of Acambis, Inc.

To March 2008 News Articles Index | To Canada Equine ...On-Line Home